ArticleCanadian liver journal2026
Metabolic dysfunction-associated steatotic liver disease assessment and management: Clinical practice guidance from the Canadian Association for the Study of the Liver.
Article in Canadian liver journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading and increasingly prevalent cause of chronic liver disease, cirrhosis, hepatocellular carcinoma, and liver transplantation in Canada. This Canadian Association for the Study of the Liver clinical practice guidance provides pragmatic recommendations for MASLD assessment and management across Canadian health care settings. Guidance statements were developed by a multidisciplinary national steering committee using the best available evidence, targeted literature review, expert consensus, and a modified Delphi process. This document summarizes Canadian epidemiology and natural history, nomenclature, identification of populations at increased risk, screening and advanced fibrosis risk stratification, federal and provincial health policy, remote and community care delivery, and management across the MASLD disease spectrum. MASLD screening is recommended for adults with type 2 diabetes mellitus, obesity, cardiometabolic risk factors, hepatic steatosis, family history of MASLD cirrhosis, or persistently abnormal liver tests. A stepwise approach for at-risk populations, using simple blood-based tests, such as FIB-4, followed by imaging elastography or Enhanced Liver Fibrosis score, to rule advanced fibrosis in or out is appropriate. For children with MASLD, a multidisciplinary approach to management is recommended and should include lifestyle counselling, cardiometabolic risk reduction, treatment of obesity and type 2 diabetes mellitus, and approved therapy for non-cirrhotic MASLD as appropriate. The guidance also highlights gaps in Canadian population-level data in disease surveillance; Indigenous, ethnic-diverse, and equity-deserving cohorts; natural history, prevalence, and risk stratification for pediatric MASLD; epidemiology of MetALD; and varying provincial access to non-invasive tests and multidisciplinary care for persons with MASLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.